buspirone has been researched along with Autism Spectrum Disorder in 3 studies
Buspirone: An anxiolytic agent and serotonin receptor agonist belonging to the azaspirodecanedione class of compounds. Its structure is unrelated to those of the BENZODIAZAPINES, but it has an efficacy comparable to DIAZEPAM.
buspirone : An azaspiro compound that is 8-azaspiro[4.5]decane-7,9-dione substituted at the nitrogen atom by a 4-(piperazin-1-yl)butyl group which in turn is substituted by a pyrimidin-2-yl group at the N(4) position.
Autism Spectrum Disorder: Wide continuum of associated cognitive and neurobehavioral disorders, including, but not limited to, three core-defining features: impairments in socialization, impairments in verbal and nonverbal communication, and restricted and repetitive patterns of behaviors. (from DSM-V)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine safety and efficacy of the 5HT1A serotonin partial agonist buspirone on core autism and associated features in children with autism spectrum disorder (ASD)." | 9.22 | Efficacy of Low-Dose Buspirone for Restricted and Repetitive Behavior in Young Children with Autism Spectrum Disorder: A Randomized Trial. ( Behen, M; Chugani, DC; Chugani, HT; Dixon-Thomas, P; Edwards, DJ; Evans, PA; Hansen, RL; Hirtz, D; Janisse, JJ; Kumar, A; Muzik, O; Nass, R; Parikh, S; Parker, JS; Rothermel, R; Wiznitzer, M, 2016) |
| "Findings from this retrospective chart review suggest a promising role of buspirone in managing anxiety among youth with HF-ASD." | 7.91 | A Retrospective Chart Review of Buspirone for the Treatment of Anxiety in Psychiatrically Referred Youth with High-Functioning Autism Spectrum Disorder. ( Biederman, J; Ceranoglu, TA; DeLeon Fong, M; Fried, R; Galdo, M; Hoskova, B; Joshi, G; Wozniak, J, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Higuchi, Y | 1 |
| Tada, T | 1 |
| Nakachi, T | 1 |
| Arakawa, H | 1 |
| Ceranoglu, TA | 1 |
| Wozniak, J | 1 |
| Fried, R | 1 |
| Galdo, M | 1 |
| Hoskova, B | 1 |
| DeLeon Fong, M | 1 |
| Biederman, J | 1 |
| Joshi, G | 1 |
| Chugani, DC | 1 |
| Chugani, HT | 1 |
| Wiznitzer, M | 1 |
| Parikh, S | 1 |
| Evans, PA | 1 |
| Hansen, RL | 1 |
| Nass, R | 1 |
| Janisse, JJ | 1 |
| Dixon-Thomas, P | 1 |
| Behen, M | 1 |
| Rothermel, R | 1 |
| Parker, JS | 1 |
| Kumar, A | 1 |
| Muzik, O | 1 |
| Edwards, DJ | 1 |
| Hirtz, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Placebo-controlled, Double-masked Clinical Trial of Buspirone in the Treatment of 2- 6 Year Old Children With Autistic Disorder[NCT00873509] | Phase 2/Phase 3 | 166 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for buspirone and Autism Spectrum Disorder
| Article | Year |
|---|---|
Efficacy of Low-Dose Buspirone for Restricted and Repetitive Behavior in Young Children with Autism Spectrum Disorder: A Randomized Trial.
Topics: Autism Spectrum Disorder; Buspirone; Child; Child Development; Child, Preschool; Female; Humans; Mal | 2016 |
2 other studies available for buspirone and Autism Spectrum Disorder
| Article | Year |
|---|---|
Serotonergic circuit dysregulation underlying autism-related phenotypes in BTBR mouse model of autism.
Topics: Animals; Autism Spectrum Disorder; Autistic Disorder; Buspirone; Disease Models, Animal; Female; Hum | 2023 |
A Retrospective Chart Review of Buspirone for the Treatment of Anxiety in Psychiatrically Referred Youth with High-Functioning Autism Spectrum Disorder.
Topics: Adolescent; Anxiety; Autism Spectrum Disorder; Brief Psychiatric Rating Scale; Buspirone; Child; Fem | 2019 |